PDF(Pubmed)
Abstract：
UNASSIGNED: Statin may confer anticancer efficacy, while the studies evaluating the influence of statin on survival of patients with renal cell cancer (RCC) yielded inconsistent results. A systematic review and meta-analysis was performed to investigate the association between statin use and survival of patients with RCC.
UNASSIGNED: Cohort studies were identified by search of PubMed, Embase, and Web of Science databases according to the objective of the meta-analysis. A random-effect model incorporating the possible between-study heterogeneity was used for meta-analysis. Subgroup analyses according to study characteristics were also performed.
UNASSIGNED: Seventeen cohort studies involving 42528 patients with RCC were available for the meta-analysis. Results showed that statin use was associated with a better overall survival (OS, hazard ratio [HR]: 0.73, 95% confidence interval [CI]: 0.65 to 0.84, p < 0.001; I2 = 40%), progression progression-free survival (PFS, HR: 0.82, 95% CI: 0.68 to 0.98, p = 0.03; I2 = 52%), and cancer-specific survival (CSS, HR: 0.76, 95% CI: 0.59 to 0.99, p = 0.04; I2 = 38%). Besides, for the outcome of OS and PFS, subgroup analyses showed similar results in patients with surgical and non-surgical anticancer treatments, and in patients with stage I-III and stage IV RCC (p values for subgroup difference all > 0.05).
UNASSIGNED: Statin use may be associated with improved survival outcomes in patients with RCC. Although prospective clinical studies should be considered to validate these results, these findings suggest that statins may be potential adjuvant therapy for patients with RCC.
UNASSIGNED: Cohort studies were identified by search of PubMed, Embase, and Web of Science databases according to the objective of the meta-analysis. A random-effect model incorporating the possible between-study heterogeneity was used for meta-analysis. Subgroup analyses according to study characteristics were also performed.
UNASSIGNED: Seventeen cohort studies involving 42528 patients with RCC were available for the meta-analysis. Results showed that statin use was associated with a better overall survival (OS, hazard ratio [HR]: 0.73, 95% confidence interval [CI]: 0.65 to 0.84, p < 0.001; I2 = 40%), progression progression-free survival (PFS, HR: 0.82, 95% CI: 0.68 to 0.98, p = 0.03; I2 = 52%), and cancer-specific survival (CSS, HR: 0.76, 95% CI: 0.59 to 0.99, p = 0.04; I2 = 38%). Besides, for the outcome of OS and PFS, subgroup analyses showed similar results in patients with surgical and non-surgical anticancer treatments, and in patients with stage I-III and stage IV RCC (p values for subgroup difference all > 0.05).
UNASSIGNED: Statin use may be associated with improved survival outcomes in patients with RCC. Although prospective clinical studies should be considered to validate these results, these findings suggest that statins may be potential adjuvant therapy for patients with RCC.
摘要：
■他汀可能赋予抗癌功效，而评估他汀类药物对肾细胞癌（RCC）患者生存率影响的研究得出的结果不一致。进行了系统评价和荟萃分析，以研究他汀类药物使用与RCC患者生存之间的关系。
■队列研究是通过搜索PubMed，Embase,和WebofScience数据库，根据荟萃分析的目标。将纳入研究间可能的异质性的随机效应模型用于荟萃分析。还根据研究特征进行了亚组分析。
■共有17项队列研究，涉及42528例RCC患者，可用于荟萃分析。结果显示，他汀类药物的使用与更好的总生存率(OS，风险比[HR]：0.73，95%置信区间[CI]：0.65至0.84，p<0.001；I2=40%），无进展进展生存期（PFS，HR：0.82，95%CI：0.68至0.98，p=0.03；I2=52%），和癌症特异性生存率(CSS，HR：0.76，95%CI：0.59至0.99，p=0.04；I2=38%）。此外,对于OS和PFS的结果，亚组分析显示，在接受手术和非手术抗癌治疗的患者中结果相似，在I-III期和IV期RCC患者中（P值亚组差异均>0.05）。
■他汀类药物的使用可能与RCC患者生存结局的改善相关。尽管应该考虑前瞻性临床研究来验证这些结果，这些发现提示他汀类药物可能是RCC患者的潜在辅助治疗.
■队列研究是通过搜索PubMed，Embase,和WebofScience数据库，根据荟萃分析的目标。将纳入研究间可能的异质性的随机效应模型用于荟萃分析。还根据研究特征进行了亚组分析。
■共有17项队列研究，涉及42528例RCC患者，可用于荟萃分析。结果显示，他汀类药物的使用与更好的总生存率(OS，风险比[HR]：0.73，95%置信区间[CI]：0.65至0.84，p<0.001；I2=40%），无进展进展生存期（PFS，HR：0.82，95%CI：0.68至0.98，p=0.03；I2=52%），和癌症特异性生存率(CSS，HR：0.76，95%CI：0.59至0.99，p=0.04；I2=38%）。此外,对于OS和PFS的结果，亚组分析显示，在接受手术和非手术抗癌治疗的患者中结果相似，在I-III期和IV期RCC患者中（P值亚组差异均>0.05）。
■他汀类药物的使用可能与RCC患者生存结局的改善相关。尽管应该考虑前瞻性临床研究来验证这些结果，这些发现提示他汀类药物可能是RCC患者的潜在辅助治疗.
